Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Marketing Established Products

Sponsored by

  • Full Results
    • Winner

      JEVTANA: NICE and FIGHT – How Sanofi Genzyme Ensured Every Man with Metastatic Castrate Resistant Prostate Cancer, Wherever He Lives in the UK, is Given the Chance for Prolonged Life

      by Sanofi Genzyme


      Finalists

      Bayer iMCM Lighthouse Project

      by Bayer
      with support from Oi Ltd

      Progression Free Living

      by Celgene


Back to Results


Winner

JEVTANA: NICE and FIGHT – How Sanofi Genzyme Ensured Every Man with Metastatic Castrate Resistant Prostate Cancer, Wherever He Lives in the UK, is Given the Chance for Prolonged Life

by Sanofi Genzyme


Summary of work

In 2015, JEVTANA® (cabazitaxel), a life-prolonging treatment for men with metastatic castrate resistant prostate cancer (mCRPC), was delisted from the Cancer Drugs Fund in England. This meant patients in England no longer had the option of a treatment giving them precious additional time with their loved ones. Patients living in Scotland, Wales and Northern Ireland had never had access to JEVTANA.

The delisting provoked a strong reaction from physicians and patients making it clear there was a genuine clinical need for JEVTANA. To secure access to life-prolonging treatment for patients across the whole of the UK, Sanofi decided it must achieve both a NICE and an SMC recommendation. To accomplish this, the company engaged with key clinicians, clinical organisations, patient advisory groups and expert patients to drive strong advocacy and engagement in the Health Technology Assessment processes. To meet the demands of NICE and SMC, Sanofi was innovative and adaptive in its solution to facilitate the cost-effective supply of JEVTANA. To achieve the challenging timelines, it had to plan meticulously and work collectively across the organisation and with customers.

The outcome is that men with mCRPC, no matter where they live in the UK, now have access to additional treatment options.

Judges' comments

The team should be proud of its persistence in a challenging environment. The evidence of strong cross-functional working, coupled with the engagement of key stakeholders, is really impressive. The project showed an increase in sales with a positive uptake. We were impressed with the programme’s successful turn-around of the brand.


Finalists

Bayer iMCM Lighthouse Project - by Bayer
with support from Oi Ltd

Progression Free Living - by Celgene


Key dates

Entry deadline 29 August 2019
Extended entry deadline 5 September 2019*
*additional fee applies
Judging day 26 September 2019
Company/Team Interviews 9 October 2019
PMEA Event 27 November 2019